The FDA apparently deems an uncontrolled study acceptable – five months after saying no.
ApexOnco Front Page
Recent articles
Could RO7851624, newly into clinical trials, be RG6735?
The Kandlelit-007 trial will assess MK-1084 plus SC Keytruda across PD-L1 expression levels.
The ESMO presidential session will feature data from Destiny-Breast05 and 11.
Keynote-D18 features among the ESMO late-breakers, but IO Biotech can't file.
Genmab acquires the Dutch biotech for $8bn.
BNT329 enters the clinic, as do four other new ADCs.
Four more failed tiragolumab trials, including Imbrave-152, will feature.